369 related articles for article (PubMed ID: 32119090)
21. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease.
Diederen K; Li JV; Donachie GE; de Meij TG; de Waart DR; Hakvoort TBM; Kindermann A; Wagner J; Auyeung V; Te Velde AA; Heinsbroek SEM; Benninga MA; Kinross J; Walker AW; de Jonge WJ; Seppen J
Sci Rep; 2020 Nov; 10(1):18879. PubMed ID: 33144591
[TBL] [Abstract][Full Text] [Related]
22. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
23. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease.
Wang Y; Gao X; Zhang X; Xiao F; Hu H; Li X; Dong F; Sun M; Xiao Y; Ge T; Li D; Yu G; Liu Z; Zhang T
Gut Microbes; 2021; 13(1):1-18. PubMed ID: 33430702
[TBL] [Abstract][Full Text] [Related]
24. Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers.
Rojas-Feria M; Romero-García T; Fernández Caballero-Rico JÁ; Pastor Ramírez H; Avilés-Recio M; Castro-Fernandez M; Chueca Porcuna N; Romero-Gόmez M; García F; Grande L; Del Campo JA
World J Gastroenterol; 2018 Dec; 24(46):5223-5233. PubMed ID: 30581271
[TBL] [Abstract][Full Text] [Related]
25. Urinary metabolic insights into host-gut microbial interactions in healthy and IBD children.
Martin FP; Su MM; Xie GX; Guiraud SP; Kussmann M; Godin JP; Jia W; Nydegger A
World J Gastroenterol; 2017 May; 23(20):3643-3654. PubMed ID: 28611517
[TBL] [Abstract][Full Text] [Related]
26. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
27. Differences in amino acid and lipid metabolism distinguish Crohn's from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis.
Adegbola SO; Sarafian M; Sahnan K; Ding NS; Faiz OD; Warusavitarne J; Phillips RKS; Tozer PJ; Holmes E; Hart AL
Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):1469-1479. PubMed ID: 33337668
[TBL] [Abstract][Full Text] [Related]
28. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
30. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
[TBL] [Abstract][Full Text] [Related]
31. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
32. Location-specific signatures of Crohn's disease at a multi-omics scale.
Gonzalez CG; Mills RH; Zhu Q; Sauceda C; Knight R; Dulai PS; Gonzalez DJ
Microbiome; 2022 Aug; 10(1):133. PubMed ID: 35999575
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
34. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
[TBL] [Abstract][Full Text] [Related]
35. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
[TBL] [Abstract][Full Text] [Related]
36. Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment.
Honap S; Meade S; Spencer A; Pavlidis P; Luber RP; Calonje E; Rashidghamat E; Bunker CB; Lewis F; Irving PM
J Crohns Colitis; 2022 Jun; 16(5):822-834. PubMed ID: 34962991
[TBL] [Abstract][Full Text] [Related]
37. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
Doherty MK; Ding T; Koumpouras C; Telesco SE; Monast C; Das A; Brodmerkel C; Schloss PD
mBio; 2018 Mar; 9(2):. PubMed ID: 29535202
[TBL] [Abstract][Full Text] [Related]
38. Faecal Bacteriome and Metabolome Profiles Associated with Decreased Mucosal Inflammatory Activity Upon Anti-TNF Therapy in Paediatric Crohn's Disease.
Hurych J; Mascellani Bergo A; Lerchova T; Hlinakova L; Kubat M; Malcova H; Cebecauerova D; Schwarz J; Karaskova E; Hecht T; Vyhnanek R; Toukalkova L; Dotlacil V; Greinerova K; Cizkova A; Horvath R; Bronsky J; Havlik J; Hradsky O; Cinek O
J Crohns Colitis; 2024 Jan; 18(1):106-120. PubMed ID: 37527838
[TBL] [Abstract][Full Text] [Related]
39. Plasma bile acids in association with Crohn's disease.
Kiasat A; Prast-Nielsen S; Rautiainen S; Engstrand L; Andersson F; Lindberg J; Schuppe-Koistinen I; Löf Granström A; Gustafsson UO
Scand J Gastroenterol; 2024 Jun; 59(6):674-682. PubMed ID: 38505982
[TBL] [Abstract][Full Text] [Related]
40. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
